Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, PD of OSE-127 in Healthy Subjects
NCT03980080Phase 1Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Dec 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lusvertikimab in ulcerative colitis (UC) and primary Sjögren's syndrome (4 arms), sponsored by OSE Immunotherapeutics. Primary endpoints: Treatment Emergent Adverse Events at 19 weeks and Anti-drug Antibody Formation at 19 weeks. Started Dec 2018; status: completed.
02
Drugs
lusvertikimab
03
Conditions
ulcerative colitis (UC)primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT03980080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980080.